Eversept Partners, LP Cytokinetics Inc Transaction History
Eversept Partners, LP
- $1.32 Billion
- Q2 2024
A detailed history of Eversept Partners, LP transactions in Cytokinetics Inc stock. As of the latest transaction made, Eversept Partners, LP holds 126,877 shares of CYTK stock, worth $6.64 Million. This represents 0.52% of its overall portfolio holdings.
Number of Shares
126,877Holding current value
$6.64 Million% of portfolio
0.52%Shares
5 transactions
Others Institutions Holding CYTK
# of Institutions
406Shares Held
126MCall Options Held
3.29MPut Options Held
2.01M-
Black Rock Inc. New York, NY14.7MShares$768 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.4MShares$599 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD8.14MShares$426 Million0.28% of portfolio
-
Wellington Management Group LLP Boston, MA7.51MShares$393 Million0.07% of portfolio
-
State Street Corp Boston, MA6.55MShares$343 Million0.02% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $4.93B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...